Eisai Inc.
Clinical trials sponsored by Eisai Inc., explained in plain language.
A pharmaceutical company focused on neurology and oncology, subsidiary of Eisai Co., Ltd.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug play nice with common medicines? a trial investigates Results expected Nov 2026 (estimated)
- Double attack on Alzheimer's: new drug combo targets tau and amyloid Results expected Dec 2026 (estimated)
- Mining medical claims: a smarter way to spot Alzheimer's complications? Results expected Dec 2026 (estimated)
- New pill aims to keep narcolepsy patients awake and safe Results expected Feb 2027 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Mar 2027 (estimated)
-
Lifeline for kids with severe epilepsy: drug access extended
Disease control Expanded accessThis program offers continued access to rufinamide for children with Lennox-Gastaut syndrome, a severe form of epilepsy, who completed a previous study. The goal is to keep providing the medication until it becomes commercially available in Poland. Only children who were already …
Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …
Phase 1/2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill aims to keep narcolepsy patients awake and safe
Symptom relief Recruiting nowThis study tests whether E2086, an oral tablet, can reduce excessive daytime sleepiness in adults with narcolepsy. About 64 participants will receive either the drug or a placebo for 4 weeks. Researchers will measure how long people can stay awake using a standard test, and also …
Phase 2 • Sponsor: Eisai Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
10-Year watch: how safe is lecanemab outside clinical trials?
Knowledge-focused Recruiting nowResearchers are following thousands of people with Alzheimer's disease who receive lecanemab-irmb in routine care to see how often serious brain side effects occur. The study uses a national registry to track brain swelling, small bleeds, seizures, allergic reactions, strokes, an…
Sponsor: Eisai Inc. • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC